The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00470808

Acronym

POMX

Enrollment

Unknown

Registered

2007-05-08

Start date

2007-05-31

Completion date

2007-08-31

Last updated

2007-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

Minors, Enrollment in another study, Males, HBA1C greater than 7, Drug therapy for DM

Brief summary

Diabetes is a highly atherogenic disease. Pomegranate juice has impressive antioxidant properties. It has been proven to decrease oxidant stress and to cause the regression of atherosclerotic plaques in hypercholestrolemic and diabetic patients.Furthermore it has been proven to potentiate the biologic activity of the enzyme paraoxonase 1 which is very important in preventing atherosclerosis. The study will try to prove that a polyphenolic extract from pomegranate (POMx) has the same desired effects.

Interventions

DRUGPOMx

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Males * HBA1C\>7% * Drug therapy given for DM

Exclusion criteria

* Age\<18 * Inclusion in another study

Countries

Israel

Contacts

Primary ContactWasseem Rock, MD

wasseem_rock@yahoo.com0547866896

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026